Public Consultation on the draft revised Pharmaceutical Benefits Advisory Committee (PBAC) Guidelines

Page last updated: 6 May 2016

Public Submissions

The call for Submissions to the public consultation process for the draft revised PBAC Guidelines (Version 5.0) closed on 5 April 2016. The Department appreciates the contribution of all organisations and individuals who made a submission. 

The submissions have been provided to the Guidelines Review Steering Committee for consideration in the finalisation of the revised PBAC Guidelines.

Privacy

Unless otherwise requested, all submissions to the Review have been published on this page.

The Department of Health has not published submissions, or parts of submissions, that contain personal information, offensive language, potentially defamatory material or copyright infringing material.

Responsibility for copyright in submissions resides with the author(s), not with the Department of Health.

All submissions have been converted to Portable Document Format (PDF) for publication and may have a different appearance to the document that was submitted.

Your submission and contact details have been stored in accordance with the Australian Privacy Principles from Schedule 1 of the Privacy Amendment (Enhancing Privacy Principles) Act 2012 and the Archives Act 2012.  Should you have any concerns about the storage of your submission, or if you wish to gain access to make a correction, please email the PBS Post Market Review team. A copy of the Department’s privacy policy is available on request. If you wish to make a complaint about the handling of your private information, you may contact the Department of Health Privacy Contact Officer on 02 6289 5773 and, if unsatisfied with the response, you may submit a complaint to the Office of the Australian Information Commissioner.

Disclaimer

• The views expressed in submissions published on this website are solely those of the contributing authors or organisations.
• The Commonwealth accepts no responsibility for the completeness or accuracy of any information contained in the submissions.
• The Commonwealth makes no representations about the suitability of the information for any particular purpose. Users of the information must make their own inquiries and assessments about those matters or seek independent advice.
• Submissions are published on the understanding that the contributing authors or organisations have copyright in the submissions either by way of ownership or a licence. They retain their copyright, and by making submissions they licence the Commonwealth to publish the submissions, unless a party when making a submission has requested that it be kept confidential and the Commonwealth clearly agrees that the submission will be kept confidential.

 

Table of Submissions

Submission	Author Name	Document Link	Date Received
1	S & J Crowley Consulting, Noble Pharma Consulting, Shoten Consulting and Wonder Drug Consulting	Submission 1 (PDF 97KB)	1/04/2016
2	Schizophrenia Fellowship of NSW Inc	Submission 2 (PDF 817KB)	1/04/2016
3	Noble Pharma Consulting	Submission 3 (PDF 25KB)	1/04/2016
4	Roche Products	Submission 4 (PDF 838KB)	4/04/2016
5	Evaluator Group	Not for publication	4/04/2016
6	Merck Serono Australia	Submission 6 (PDF 635KB)	4/04/2016
7	Evaluator Group	Not for publication	4/04/2016
8	Industry Organisation	Not for publication	5/04/2016
9	HTAccess Consulting	Submission 9 (PDF 235KB)	5/04/2016
10	Medicines Australia	Submission 10 (PDF 356KB)	5/04/2016
11	SANE Australia	Submission 11 (PDF 26KB)	5/04/2016
12	Evaluator Group	Not for publication	5/04/2016
13	MSD	Submission 13 (PDF 204KB)	5/04/2016
14	Shoten Consulting	Submission 14 (PDF 2.4MB)	5/04/2016
15	Takeda Pharmaceuticals Australia	Submission 15 (PDF 1.3MB)	5/04/2016
16	Metabolic Dietary Disorders Association	Submission 16 (PDF 103KB)	5/04/2016
17	Mental Health Australia	Submission 17 (PDF 489KB)	5/04/2016
18	NPS MedicineWise	Submission 18 (PDF 143KB)	5/04/2016
19	Non-Government organisation	Not for publication	5/04/2016
20	Non-Government organisation	Not for publication	5/04/2016
21	Institute for Innovation and Valuation in Health Care	Submission 21 (PDF 1.6MB)	5/04/2016
22	Bayer Australia	Submission 22 (PDF 6.5MB)	5/04/2016
23	Lundbeck Australia	Submission 23 (PDF 455KB)	5/04/2016
24	Evaluator Group	Not for publication	5/04/2016
25	Pfizer Australia	Submission 25 (PDF 4.1MB)	5/04/2016
26	Rare Voices Australia	Submission 26 (PDF 190KB)	5/04/2016
27	Consumer	Submission 27 (PDF 17KB)	5/04/2016
28	Sanofi	Submission 28 (PDF 950KB)	5/04/2016
29	Optum on behalf of the Rare Disease Industry Working Group	Submission 29 (PDF 131KB)	5/04/2016
30	Industry Organisation	Not for publication	5/04/2016
31	Evaluator Group	Not for publication	5/04/2016
32	Janssen Cilag	Submission 32 (PDF 320KB)	5/04/2016
33	AstraZeneca	Submission 33 (PDF 81KB)	5/04/2016
34	Novo Nordisk Pharmaceuticals	Submission 34 (PDF 259KB)	5/04/2016
35	Vertex Pharmaceuticals Australia	Submission 35 (PDF 312KB)	5/04/2016
36	Consumer	Submission 36 (PDF 103KB)	5/04/2016
37	AbbVie	Submission 37 (PDF 52KB)	5/04/2016
38	Optum	Submission 38 (PDF 122KB)	5/04/2016
39	GlaxoSmithKline	Submission 39 (PDF 3.4MB)	5/04/2016
40	Cancer Drugs Alliance	Submission 40 (PDF 469KB)	6/04/2016
41	Royal Australian and New Zealand College of Psychiatrists	Submission 41 (PDF 65KB)	6/04/2016
42	THEMA Consulting	Submission 42 (PDF 179KB)	6/04/2016
43	Wonder Drug Consulting	Submission 43 (PDF 357KB)	12/04/2016